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Optical coherence tomography (OCT) has been recently applied to investigate cor-
onary artery disease in interventional cardiology. Compared to intravascular ultra-
sound, OCT is able to visualize various vascular structures more clearly with high-
er resolution. Several validation studies have shown that OCT is more accurate in 
evaluating neointimal tissue after coronary stent implantation than intravascular 
ultrasound. Novel findings on OCT evaluation include the detection of strut cover-
age and the characterization of neointimal tissue in an in-vivo setting. In a previous 
study, neointimal healing of stent strut was pathologically the most important fac-
tor associated with stent thrombosis, a fatal complication, in patients treated with 
drug-eluting stent (DES). Recently, OCT-defined coverage of a stent strut was pro-
posed to be related with clinical safety in DES-treated patients. Neoatherosclerosis 
is an atheromatous change of neointimal tissue within the stented segment. Clini-
cal studies using OCT revealed neoatherosclerosis contributed to late-phase lumi-
nal narrowing after stent implantation. Like de novo native coronary lesions, the 
clinical presentation of OCT-derived neoatherosclerosis varied from stable angina 
to acute coronary syndrome including late stent thrombosis. Thus, early identifica-
tion of neoatherosclerosis with OCT may predict clinical deterioration in patients 
treated with coronary stent. Additionally, intravascular OCT evaluation provides 
additive information about the performance of coronary stent. In the near future, 
new advances in OCT technology will help reduce complications with stent thera-
py and accelerating in the study of interventional cardiology.
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Although bare-metal stents (BMS) show better outcomes than balloon angioplasty 
in reducing acute vessel closure,1,2 in-stent restenosis (ISR) of treated coronary ar-
teries still remains a challenge. Pathologic studies have revealed that neointimal 
tissue within stented segments mainly consist of smooth muscle cells and extracel-
lular matrix.3,4 Thus, the inhibition of smooth muscle cell has been a therapeutic 
target of percutaneous coronary intervention for reducing overwhelming growth of 
neointimal tissue. Compared to BMS, drug-eluting stents (DES) show remarkably 
reduced rates of angiographic restenosis and improved clinical outcomes.5,6 There-
fore, DES, which comprises a metallic stent frame, anti-proliferative drugs and 
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min vs. 11.2±2.5 min, p<0.01) and a higher acquisition rate 
of clear images (99.4% vs. 80.8%, p<0.01) than time-do-
main OCT.11 Additionally, frequency-domain OCT was not 
related to any adverse cardiac events.11 Frequency-domain 
OCT showed better detection of incomplete stent apposi-
tion (malapposition) or uncovered strut, compared with 
IVUS.12,13
STENT STRUT APPOSITION
In IVUS study, incomplete stent apposition is defined as a 
separation of at least one stent strut from the intimal surface 
of the arterial wall that is not overlapping a side branch and 
has evidence of blood flow behind the strut.14 OCT enables 
one to observe apposition of a stent strut more accurately 
compared to IVUS; malapposed stent struts on OCT are de-
fined as a distance between the strut marker and lumen con-
tour greater than the strut thickness plus the axial resolution 
of OCT.15 Accordingly, definitions of malapposed struts dif-
fer according to type of coronary stent because the thick-
ness of struts and applied polymer vary. Fig. 1 shows typi-
cal examples of well-apposed and malapposed struts. The 
following are thresholds of malapposed struts for several 
DESs; ≥160 µm for sirolimus-eluting stent (Cypher Se-
lect™, Cordis, Miami Lake, FL, USA), ≥130 µm for pacli-
taxel-eluting stent (Taxus LiberteTM, Boston Scientific, 
Natick, MA, USA), ≥110 µm for zotarolimus-eluting stent 
(EndeavorTM and ResoluteTM, Medtronic, Santa Rosa, CA, 
USA), ≥100 μm for everolimus-eluting stents (XienceTM, 
Abbott Vascular, Santa Clara, CA, USA) and ≥130 μm for 
biolimus-eluting stent (NoboriTM, Terumo Corporation, To-
kyo, Japan or BioMatrixTM, Biosensors Interventional, Sin-
gapore).16-19
As neointimal tissue proliferates after stent implantation, 
malapposed struts usually disappear when the distance be-
tween the stent strut and vessel wall is short.16,20-22 Previous 
OCT study showed that the percentage of malapposed 
struts with minimal malapposition decreased from 12.2± 
11.0% post-intervention to 1.0±2.2% after about 6 months 
of follow-up.16 However, some struts are persistently 
malapposed after an index procedure (persistent malapposi-
tion) and some are newly detected at follow-up (late-ac-
quired malapposition). Although the healing process of 
malapposed struts has not yet been clearly addressed, re-
cent OCT studies showed incomplete stent apposition was 
more likely to be sustained as its distance (or area) was far 
polymer, has been the main agent for treating coronary ar-
tery disease until now. While DES is considered an ideal 
treatment modality for coronary artery disease, this benefit 
has been challenged with the emergence of stent thrombo-
sis, a serious complication. According to recent registries, 
the rate of late stent thrombosis was 0.53% per year and 
steadily increased to 3% over 4 years in first-generation 
DES-treated patients.7,8 Accordingly, balance between the 
efficacy and safety of DES should be considered in DES 
implantation in patients with coronary artery disease. As 
optical coherence tomography (OCT) has enabled the ob-
servation of delicate coronary vessels and stents with supe-
rior resolution, a number of OCT studies have investigated 
DES-treated lesions in various clinical situations. There-
fore, we sought to review recent advances in OCT focusing 
on DES-treated lesions.
OCT VS. INTRAVASCULAR 
ULTRASOUND
Intravascular ultrasound (IVUS) has been the standard im-
aging modality for evaluating the status of a coronary stent. 
However, it is limited in evaluating neointimal tissue within 
the stented segment due to its low resolution. Contrary to 
IVUS, OCT has a resolution of 10-20 μm, which is about 
10 times higher than that of IVUS (80-120 μm). Previous 
studies have shown the superiority of OCT over IVUS in 
relation to resolution capacity. Compared to IVUS, OCT 
showed better diagnostic accuracy for detecting a small de-
gree of in-stent neointima, which was defined as occupying 
<30% of the stent area measured with histology.9 The opti-
cal cutoff value of percent neointimal hyperplasia (NIH) 
cross-sectional area (CSA) for detecting NIH by IVUS was 
14.7%; OCT-measured neointimal tissue of percent NIH 
CSA <14.7% cannot be detected with IVUS.10 
Recently, time-domain OCT systems have evolved to 
next-generation frequency-domain OCT systems. In the 
former system, an occlusion balloon was inflated and lac-
tated Ringer’s solution was infused through a catheter for 
acquiring OCT images. However, the frequency-domain 
OCT system is able to generate frames at much higher rates 
and allows for faster pullback speeds. Instead of the occlu-
sion balloon, contrast medium is continuously flushed at a 
rate of 4 to 5 mL/s for 3 to 4 seconds. In an OCT study to 
evaluate the feasibility of frequency-domain OCT, frequen-
cy-domain OCT showed shorter procedural time (3.2±0.8 
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delayed neointimal coverage of a DES is somewhat to be 
expected. However, even after the anti-proliferative drug is 
completely eluted into the adjacent wall, DES struts fre-
quently remain uncovered upon ex- and in-vivo examination 
of implanted stents.28-30 Few sirolimus-eluting stents show 
complete coverage at 6 months post-intervention.29 For pacl-
itaxel-eluting stents, another first-generation DES, one study 
also showed that the incidence of completely covered stents 
was 29.6% at 9 months post-intervention.30 Consequently, 
patients treated with first-generation DES should receive 
dual anti-platelet therapy (aspirin and clopidogrel) for a lon-
ger time than those that received a BMS. To overcome the 
above limitation with first-generation DES, new-generation 
DESs have been developed with an advanced strut platform, 
polymer and new anti-proliferative drugs.
Table 1 summarizes the strut apposition and coverage of 
various DESs. Compared to sirolimus-eluting stent, the 
coverage of Endeavor zotarolimus-eluting stent was almost 
complete at 3 months.31 The rate of stent thrombosis was 
0.2% during 1-year follow-up in patients that received only 
3-month dual anti-platelet therapy following Endeavor zo-
tarolimus-eluting stent implantation in the REal Safety and 
Efficacy of 3-month dual antiplatelet Therapy (RESET) tri-
al to evaluate the safety and efficacy thereof.32 Resolute zo-
tarolimus-eluting stent also showed higher rates of strut 
coverage than sirolimus-eluting stent at 9 months,17 as did 
everolimus-eluting stent.18 The Swedish Coronary Angiog-
raphy and Angioplasty Registry (SCAAR) data revealed 
that the rates of restenosis and definite stent thrombosis in 
these new-generation DESs were lower than that of first-
generation DESs.33 Biolimus-eluting stent has the unique 
property of a biodegradable polymer with abluminal coat-
from the vessel wall;21,22 a strut-to-vessel distance of ≤260 
µm on post-stenting OCT images was suggested as a cut-
off value for resolved malapposition of first-generation 
DES.22 Additionally, in other study, coverage of malap-
posed struts was delayed with respect to well-apposed strut 
at 9 to 13 months of follow-up after DES implantation.23 
Although overall malapposed struts were positively corre-
lated with uncovered struts, a subgroup of lesions with min-
imal stent malapposition showed similar rates of uncovered 
struts to those without malapposition.24 The coverage of 
malapposed struts was also affected by DES type, first- vs. 
new-generation DESs.25 
STENT STRUT COVERAGE
A number of OCT studies have evaluated the in-vivo status 
of DES at various time points after stent implantation. Ac-
cording to these reports, the healing of DES was quite slow 
and heterogeneous even several years after stent implanta-
tion.20,26,27 Neointimal growth after stent implantation is con-
sidered part of the wound healing process that generally oc-
curs after injury.3 This process generally consists of three 
phases: 1) an inflammatory phase (platelet aggregation and 
inflammatory cell infiltration), 2) a granulation phase (mi-
gration and proliferation of endothelial cells, fibroblasts or 
smooth muscle cells from adjacent tissue) and 3) a matrix 
remodeling phase (production of proteoglycan from fibro-
blasts and smooth muscle cells).3 By these steps, BMSs are 
fully covered with neointima about 1 month after stent im-
plantation.3 Because anti-proliferative drugs with DES in-
hibits the migration and proliferation of smooth muscle cells, 
Fig. 1. Representative images of well-apposed vs. malapposed struts. Optical coherence tomography shows well-apposed struts with 
complete coverage 9 months after drug-eluting stent implantation (A), whereas some struts (arrowheads) show incomplete stent apposi-
tion and uncovered portions to the lumen (B).
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Seung-Yul Lee and Myeong-Ki Hong
Yonsei Med J   http://www.eymj.org   Volume 54   Number 5   September 20131078
over time. 
A recent autopsy study revealed delayed neointimal heal-
ing of implanted stent was associated with occurrence of 
late stent thrombosis; the odds ratio of a stent with a ratio of 
uncovered to total stent struts per section >30% was 9.0 
(95% confidence interval, 3.5 to 22) for stent thrombosis.28 
In a case-control study in which OCT was performed at on-
set of stent thrombosis, the length of an uncovered stent 
strut segment was significantly associated with stent throm-
bosis.36 Strut coverage assessed by OCT may be a surrogate 
marker for predicting catastrophic cardiovascular events in 
daily clinical practice. One OCT study suggested that a great-
er percentage of uncovered struts (a cut-off value of ≥5.9% 
uncovered struts), as assessed by OCT at 6-18 months fol-
low-up, in asymptomatic DES-treated patients might pre-
dict increases in major adverse cardiac events related with 
stent safety in the future.37 
In quantitative OCT analysis, stent and luminal CSA are 
measured, and NIH CSA is then calculated as the stent CSA 
minus the luminal CSA. Percentage of NIH CSA is calcu-
lated as NIH CSA×100/stent CSA. NIH thickness, the dis-
tance between the endoluminal surface of neointima and 
the strut, can be measured inside all struts as a line perpen-
dicular to the neointima and strut.38 An uncovered strut is 
defined as having a NIH thickness of 0 µm.38 The percent-
age of malapposed or uncovered struts in each stented le-
sion can be calculated as the (number of malapposed or un-
ing. In a sub-study of the Limus Eluted from A Durable vs. 
ERodable Stent coating (LEADERS) trial, OCT-defined 
coverage of biolimus-eluting stent was greater than that of 
sirolimus-eluting stent at 9 months.34 The superiority of bio-
limus-eluting stent translated into greater clinical safety 
during 4-year follow-up; late definite stent thrombosis oc-
curred less frequently in patients treated with biolimus-elut-
ing stent.35 Fig. 2 depicts various rates of DES coverage 
Table 1. Strut Apposition and Coverage of Drug-Eluting Stent Assessed by Optical Coherence Tomography
Study Stent type
Follow-up 
(months)
Malapposed strut* 
(%)
Uncovered strut* 
(%)
Matsumoto, et al.29 CypherTM   6  1.2 11
Kim, et al.30 Cypher SelectTM vs. Taxus LiberteTM   9  2.6 vs. 1.5 12.5 vs. 4.9
Kim, et al.56 Endeavor SprintTM   3  0.2   0.1
Kim, et al.31 Endeavor SprintTM vs. Cypher SelectTM   9  0.1 vs. 2.6   0.3 vs. 12.3
Kim, et al.17 Endeavor ResoluteTM vs. CypherTM   9  0.1 vs. 1.5   4.4 vs. 10.3
Kim, et al.57 Endeavor ResoluteTM vs. Xience VTM   3  0.7 vs. 0.7   6.2 vs. 4.7
Gutiérrez-Chico, et al.58 Endeavor ResoluteTM vs. Xience VTM 13  1.8 vs. 1.4   7.4 vs. 5.8
Inoue, et al.59 PromusTM   8  1.8   1.6
Takano, et al.60 Xience VTM or PromusTM vs. Taxus ExpressTM   6  2.1 vs. 5.7   2.3 vs. 5.2
Choi, et al.18 Everolimus- vs. Sirolimus-eluting stent   9  0.4 vs. 1.7   4.4 vs. 10.5
Barlis, et al.34 BioMatrix FlexTM vs. Cypher SelectTM   9  0.2 vs. 0.4†   0.6 vs. 2.1†
Gutiérrez-Chico, et al.19 BioMatrix FlexTM vs. Cypher SelectTM
  9  0.5 vs. 1.4†   2.8 vs. 5.7†
24  0.1 vs. 0.4†   1.5 vs. 1.8†
Kim, et al.61
Cypher SelectTM 9 vs. 24  1.7 vs. 0.6 10.9 vs. 6.5
Taxus LiberteTM 9 vs. 24  1.0 vs. 0.3   4.0 vs. 3.7
*Values were presented as the percentage of strut which was divided by total number of analyzable struts.15
†Values were derived from Bayesian hierarchical models.
Fig. 2. Strut coverage of drug-eluting stent (DES) over time. A dot repre-
sents each of the studies in Table 1, except for Bayesian hierarchical mod-
els. A curved line represents estimated change of uncovered strut after 
DES implantation. Usage of sirolimus-eluting stent and incomplete stent 
apposition increases the risk of delayed coverage after DES implantation.
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ered patterns of neointima were more frequently observed 
in ISR lesions than in non-ISR lesions.40 However, to clari-
fy the clinical implications of different neointimal features, 
further investigations are needed. 
Neoatherosclerosis refers to an atherosclerotic change in 
neointimal tissue, which is histologically defined as clusters 
of lipid-laden foamy macrophages within the neointima 
with or without necrotic core formation.41 On OCT images, 
lipidic neointima is shown as diffusely bordered, signal-poor 
regions with overlying signal-rich bands; calcific neointima 
shows well-delineated, signal-poor regions with sharp bor-
ders.15,42 OCT-defined neoatherosclerosis is mainly confined 
to lipidic or calcific neointima.43,44 Representative images of 
neoatherosclerosis are shown in Fig. 3. Neoatherosclerotic 
change in neointima occurs in both BMS and DES.41,43 Pre-
vious histologic study found that neoatherosclerosis was 
observed more frequently and earlier in DES compared to 
BMS.41 This finding was also shown in an OCT study,43 
suggesting incomplete endothelization might be involved in 
acceleration of atherogenesis inside neointima. Neoathero-
sclerosis contributes to late-phase luminal narrowing after 
stent implantation.45,46 Previous angiographic study re-
vealed that the luminal diameter of BMS followed a bipha-
sic pattern of early narrowing and late improvement be-
tween 6 months and 3 years.47 On the other hand, the 
neointima of DES continuously progressed up to 5 years.48 
covered struts/total number of struts in all cross-sections of 
the lesion)×100, respectively.
CHARACTERIZATION OF NEOINTIMAL 
TISSUE AND NEOATHEROSCLEROSIS
Because the NIH within stent segments mainly consists of 
smooth muscle cells and extra-cellular matrix, the predomi-
nant pattern of NIH by IVUS evaluation has been presented 
as a homogenous appearance.10 However, one OCT study 
reported that various patterns of neointimal tissue develop 
in ISR lesions, suggesting that the mechanism for ISR 
might be complicated.39 Fig. 3 shows homogeneous, het-
erogeneous and layered patterns of neointimal tissue. Dif-
ferences in optical property and backscattering pattern arise 
from the heterogeneity of neointimal tissue, which contains 
various components such as fibrin accumulation, excessive 
inflammation (hypersensitivity reaction), extra-cellular ma-
trix or in-stent neoatherosclerosis, as well as smooth muscle 
cells.13 Therefore, it is difficult to conclude that specific 
types of neointimal tissue seen by OCT imply consistent 
histopathologic findings. Instead, observation of diverse 
neointima indicates that the healing process after stent de-
ployment is not stable and may be associated with clinical 
events. An OCT study showed that heterogeneous or lay-
Fig. 3. Various patterns of neointimal tissue. (A) Homogeneous pattern, (B) heterogeneous pattern, (C) layered pattern, (D) lipid-laden neointima, (E) neointi-
ma with calcification.
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penetration depth of about 2 mm and is not able to visualize 
structures behind severely attenuated components such as 
lipid-laden neointima or thrombus. In contrary to IVUS, 
blood in coronary arteries should be eliminated to acquire ad-
equate OCT images because blood scatters light. For this 
purpose, continuous flush of saline or contrast media has 
been applied. Since frequency-domain OCT utilizes a faster 
authorized pullback system than time-domain OCT, it takes 
less time to inject contrast media. Nevertheless, it is inevita-
bly necessary to create a blood-free field due to the natural 
limitation of optics. The current OCT system is not able to 
discriminate fibrin accumulation, excessive inflammation, 
abundant extracellular matrix, or neoatherosclerosis, because 
these are similarly shown as a dark appearance on OCT.13,51 
FUTURE DIRECTIONS
Three-dimensional OCT technology is now under investi-
gation for evaluating coronary artery disease. Three-dimen-
sional OCT reconstruction allows researchers to analyze 
planes which are not visible on two-dimensional images.52 
Although three-dimensional OCT technology is still time-
consuming, this application has been applied to the assess-
ment of bifurcated lesion and coronary stent.52,53 An OCT 
study showed that three-dimensional OCT reconstruction 
was feasible for evaluating the orifices of side-branch ves-
sels after stent implantation.52 Fig. 4 represents a contour 
map analysis for evaluating the status of a coronary stent 
strut.53 By this approach, the performance of a coronary 
stent could be easily visualized at a glance. Tissue character-
ization with OCT remains a challenge because tissue com-
ponents vary and some appear similarly on OCT. Several 
OCT techniques are being developed to enhance the differ-
entiation of tissue components. Polarization-sensitive OCT 
is a novel technique that can be used to measure the polar-
ization properties of backscattered light.54 Cellular targeting 
agents such as fluorophores may be useful to characterize 
neointimal tissues, combined with hybrid OCT systems.55
CONCLUSION
Utilizing the high resolution of OCT, several OCT studies 
have evaluated the in-vivo status of DES. The OCT-derived 
detection of an uncovered strut or neoatherosclerosis may be 
of use in preventing and predicting adverse cardiac events 
An OCT study showed thin-cap fibroatheroma-like neointi-
ma was more commonly detected in very late ISR lesions 
(>3 years) than in early ISR lesions (<1 year).46 Another se-
rial OCT study also demonstrated that the frequency of 
neoatherosclerosis in DES-treated lesions increased be-
tween 9 months and 2 years.26 Clinical presentation of neo-
atherosclerosis varies from stable angina to stent thrombo-
sis. Compared to patients with stable angina, patients with 
unstable angina show higher incidences of OCT-defined 
thin-cap fibroatheroma, intimal rupture and thrombi.49 In 
addition, OCT-defined rupture of lipidic neointima was ob-
served in patients with very late stent thrombosis.50 Al-
though one OCT study suggested that risk factors of neoath-
erosclerosis were similar to those of native coronary artery 
disease,44 the mechanism of neoatherosclerotic change re-
mains unknown and needs to be investigated in the future.
LIMITATIONS
Although OCT is a recent advancement in intravascular im-
aging, a number of limitations remain. OCT has a shallow 
Fig. 4. Contour plot of strut coverage after drug-eluting stent implantation, 
using optical coherence tomography. The contour plot shows detailed in-
formation about the position and coverage of stent strut, in which the cir-
cumferential arc is plotted along the X axis and the stent length is plotted 
along the Y axis. Blue circles represent uncovered struts, red circles repre-
sent malapposed struts, and orange circles represent struts crossing over 
a side-branch vessel.53 
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such as the stent thrombosis. Moreover, advances in OCT 
technology are expected to reveal detailed changes in coro-
nary stents and to widen the practical usefulness thereof. 
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